Amgen Inc EV/EBITDA
Data as of August 04, 2026
EV/EBITDA
17.30
Enterprise Value
$249.76B
EBITDA (TTM)
$14.43B
Sector
Biotechnology
How It's Calculated
17.30 = $249.76B ÷ $14.43B
What This Means
Amgen Inc's EV/EBITDA of 17.3 is in a moderate range for Biotechnology.
About Amgen Inc
Amgen Inc (AMGN) operates in the Biotechnology sector, specifically in Biotechnology. With a market capitalization of about $207.87B, it ranks as a mega-cap stock — one of the largest publicly traded companies.
Shares recently traded near $378.87, within a 52-week range of $269.77 to $398.00 (-4.8% from the high, +40.4% from the low). Beta of 0.42 indicates relatively lower volatility versus the market.
Trailing profit margin is about 21.0%, signaling a solid profit margin for its industry.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Amgen Inc, the ratio should be read with growth, capex needs, and cycle position in Biotechnology. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 17.30x EV/EBITDA, Amgen Inc (AMGN) carries an elevated EV/EBITDA multiple that may embed growth expectations or scarcity within its peer set. Enterprise value of about $249.76B and EBITDA near $14.43B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the AMGN metrics hub for related valuation pages.
Sector Comparison
Among Biotechnology names on our S&P 100 coverage, Amgen Inc's EV/EBITDA of 17.30 can be compared with peers such as GILD (16.28), REGN (19.21). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Biotechnology stocks.
Key Takeaways
- AMGN is grouped in the Biotechnology sector for peer comparisons.
- Recent beta of 0.42 suggests lower-than-market price sensitivity.
- Trailing profit margin of 21.0% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for AMGN.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other AMGN Metrics
Frequently Asked Questions
What is AMGN's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Amgen Inc's ratio is about 17.30 — common for comparing leveraged companies in Biotechnology.
Is 17.30 high or low vs peers?
Among Biotechnology peers (e.g. REGN (19.21), GILD (16.28)), AMGN's 17.30 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →